Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?

Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women, potentially due to ineffectiveness of screening tests for early detection. Patients typically present with advanced disease at diagnosis, whereas, up to 80% relapse and the estimated median progression-free s...

Descripción completa

Detalles Bibliográficos
Autores principales: Boussios, Stergios, Moschetta, Michele, Karihtala, Peeter, Samartzis, Eleftherios P., Sheriff, Matin, Pappas-Gogos, George, Ozturk, Mehmet Akif, Uccello, Mario, Karathanasi, Afroditi, Tringos, Michail, Rassy, Elie, Pavlidis, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article on Ovarian Cancer: State of the Art and Perspectives of Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812175/
https://www.ncbi.nlm.nih.gov/pubmed/33490218
http://dx.doi.org/10.21037/atm.2020.03.156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812175/
https://www.ncbi.nlm.nih.gov/pubmed/33490218
http://dx.doi.org/10.21037/atm.2020.03.156

Ejemplares similares